2. Search Result
Search Result
Results for "

1mt

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

4

Peptides

3

Recombinant Proteins

3

Isotope-Labeled Compounds

4

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0014
    Ramelteon
    Maximum Cited Publications
    12 Publications Verification

    TAK-375

    		 Melatonin Receptor Neurological Disease Endocrinology Cancer
    Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation [1] .
    Ramelteon
  • HY-P4931
    Mca-KPLGL-Dap(Dnp)-AR-NH2
    1 Publications Verification

    		 MMP Cancer
    Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 (FS-6) is a fluorescent peptide that is a quenched MMP peptide substrate. Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 can be used for real-time quantification of MMP enzymatic activity. Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 is an elongated peptide of MMP substrate (FS-1) and is active against collagenases (MMP-1, MMP-8, MMP-13 ) and MT1-MMP with higher specificity constants than FS-1 [1]. (Ex/Em=325 nm/400 nm)
    Mca-KPLGL-Dap(Dnp)-AR-NH2
  • HY-101176
    2-Iodomelatonin
    2 Publications Verification

    		 Melatonin Receptor Cancer
    2-Iodomelatonin is a potent agonist of melatonin receptor 1 (MT1) with a Ki value of 28 pM, it is more 5-fold selective for MT1 over MT2 [1]. 2-iodomelatonin can be used to identify, characterize and localize melatonin binding sites in the brain and peripheral tissues [1].
    2-Iodomelatonin
  • HY-A0014S1
    Ramelteon-d3

    TAK-375-d3

    		 Melatonin Receptor Others
    Ramelteon-d3 (TAK-375-d3) is a deuterium-labelled Ramelteon (HY-A0014). Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation.
    Ramelteon-d3
  • HY-P4123
    TAT (47-57) GGG-Cys(Npys)

    		MMP Cardiovascular Disease Inflammation/Immunology Cancer
    TAT (47-57) GGG-Cys (Npys) is a cell-penetrating peptide and delivery carrier derived from TAT. TAT (47-57) GGG-Cys (Npys) facilitates the translocation of conjugated drug molecules across cell membranes. TAT (47-57) GGG-Cys (Npys) acts as a delivery carrier for MT1-MMP inhibitors. TAT (47-57) GGG-Cys (Npys) is applicable to research on diseases associated with MT1-MMP activity, such as cancer, arthritis, heart disease, and vascular disorders [1].
    TAT (47-57) GGG-Cys(Npys)
  • HY-105285
    Piromelatine
    2 Publications Verification

    Neu-P11

    		 Melatonin Receptor 5-HT Receptor P2X Receptor TRP Channel Sodium Channel Neurological Disease
    Piromelatine (Neu-P11) is a melatonin MT1/MT2 receptor agonist, serotonin 5-HT1A/5-HT1D agonist, and serotonin 5-HT2B antagonist. Piromelatine (Neu-P11) possesses sleep promoting, analgesic, anti-neurodegenerative, anxiolytic and antidepressant potentials. Piromelatine (Neu-P11) also possesses pain-related P2X3, TRPV1, and Nav1.7 channel-inhibition capacities [1] .
    Piromelatine
  • HY-A0014S
    Ramelteon-d5

    TAK-375-d5

    		 Isotope-Labeled Compounds Melatonin Receptor Neurological Disease Endocrinology Cancer
    Ramelteon-d5 is deuterium labeled Ramelteon. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation [1] .
    Ramelteon-d5
  • HY-RS14893
    TOP1MT Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    TOP1MT Human Pre-designed siRNA Set A contains three designed siRNAs for TOP1MT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TOP1MT Human Pre-designed siRNA Set A
    TOP1MT Human Pre-designed siRNA Set A
  • HY-P10775
    BT1769

    		Peptide-Drug Conjugates (PDCs) MMP Cancer
    BT1769 is a MT1-MMP-targeted (KD = 3.35 nM) Bicycle toxin conjugate. BT1769 can be used in the study for osteosarcoma. BT1769 consists of a novel bicyclic targeting peptide that selectively binds MT1-MMP; a cytotoxin MMAE; and an enzymatically cleavable dipeptide linker [1].
    BT1769
  • HY-P10775A
    BT1769 acetate

    		MMP Cancer
    BT1769 acetate is a conjugate and antitumor agent targeting MT1-MMP, with a Kd value of 3.35 nM against human targets. BT1769 acetate exhibits favorable pharmacokinetic properties. BT1769 acetate specifically binds to MT1-MMP via its bicyclic peptide component, delivering the cytotoxic agent MMAE (HY-15162) to antigen-expressing cells. It effectively inhibits tumor growth, induces complete responses, and significantly prolongs event-free survival in osteosarcoma patient-derived xenograft models. BT1769 acetate shows extremely low activity in Ewing sarcoma models and can be used in osteosarcoma-related research [1] .
    BT1769 acetate
  • HY-176436S
    GW-117

    		Isotope-Labeled Compounds 5-HT Receptor Melatonin Receptor Neurological Disease
    GW-117 is a 5-HT2C receptor antagonist and a melatonin (MT1/MT2) receptor agonist. GW-117 shows antidepressant-like and anxiolytic-like effects [1].
    GW-117
  • HY-A0014R
    Ramelteon (Standard)

    TAK-375 (Standard)

    		 Reference Standards Melatonin Receptor Neurological Disease Endocrinology Cancer
    Ramelteon (Standard) is the analytical standard of Ramelteon. This product is intended for research and analytical applications. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation [1] .
    Ramelteon (Standard)
  • HY-122241
    MT477

    		PKC Cancer
    MT477 is a potent protein kinase C (PKC) inhibitor. MT477 induces apoptosis and necrosis. MT477 decreases the protein expression of Ras-GTP, p-Erk1/2, p-Elk1. MT477 shows antitumor activity [1].
    MT477
  • HY-105285R
    Piromelatine (Standard)

    Neu-P11 (Standard)

    		 Reference Standards Melatonin Receptor 5-HT Receptor P2X Receptor TRP Channel Sodium Channel Neurological Disease
    Piromelatine (Standard) is the analytical standard of Piromelatine. This product is intended for research and analytical applications. Piromelatine (Neu-P11) is a melatonin MT1/MT2 receptor agonist, serotonin 5-HT1A/5-HT1D agonist, and serotonin 5-HT2B antagonist. Piromelatine (Neu-P11) possesses sleep promoting, analgesic, anti-neurodegenerative, anxiolytic and antidepressant potentials. Piromelatine (Neu-P11) also possesses pain-related P2X3, TRPV1, and Nav1.7 channel-inhibition capacities [1] .
    Piromelatine (Standard)
  • HY-101176R
    2-Iodomelatonin (Standard)

    		Reference Standards Melatonin Receptor Cancer
    2-Iodomelatonin (Standard) is the analytical standard of 2-Iodomelatonin. This product is intended for research and analytical applications. 2-Iodomelatonin is a potent agonist of melatonin receptor 1 (MT1) with a Ki value of 28 pM, it is more 5-fold selective for MT1 ?over MT2 [1]. 2-iodomelatonin can be used to identify, characterize and localize melatonin binding sites in the brain and peripheral tissues [1].
    2-Iodomelatonin (Standard)
  • HY-115304
    UCM 793

    		Melatonin Receptor Neurological Disease
    UCM 793 is a non-selective MT1/MT2 receptor agonist (pKis: 9.09 (MT1 receptor); 9.19 (MT2 receptor)). UCM793 increases the number of episodes and decreases the length of the episodes of wakefulness. UCM 793 influences quality of the vigilance states. UCM 793 decreases sleep onset without having an effect on NREM sleep maintenance [1] .
    UCM 793
  • HY-183626
    TM5614 sodium

    		PAI-1 Ser/Thr Protease Furin MMP Notch Apoptosis Inflammation/Immunology Cancer
    TM5614 sodium is an orally active and specific PAI-1 inhibitor with an IC50 of <6.95 μM. TM5614 sodium blocks the interaction between PAI-1 and serine proteases or LRP-1, and enhances plasmin generation. TM5614 sodium restores macrophage efferocytosis and promotes macrophage polarization. TM5614 sodium alleviates PAI-1-mediated inhibition of Furin, promotes MT1-MMP maturation, activates the NOTCH1 signaling pathway, inhibits proliferation and induces apoptosis. TM5614 sodium promotes skeletal muscle regeneration and alleviates inflammation in a mouse model of skeletal muscle injury. TM5614 sodium can be used in research on skeletal muscle injury-induced inflammation and chronic myeloid leukemia [1] .
    TM5614 sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: